Want to join the conversation?
$FOSL 2Q15 Call: Generated operating cash flow of $78MM vs. $59MM in 2Q14. Invested $60MM in capital expenditures and $103MM to purchase roughly 1.2MM shares of the company’s common stock at an average price of $82. Ended the quarter with $842MM remaining on share repurchase authorization.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.